Russell Investments Group
AUPH icon

Russell Investments Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Russell Investments Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
131,474
+10,511
+9% +$168K ﹤0.01% 2033
2026
Q1 		$1.79M Buy
120,963
+2,798
+2% +$40.9K ﹤0.01% 1932
2025
Q4 		$1.88M Buy
118,165
+14,136
+14% +$200K ﹤0.01% 1897
2025
Q3 		$1.15M Buy
104,029
+21,520
+26% +$235K ﹤0.01% 2151
2025
Q2 		$699K Buy
82,509
+4,666
+6% +$37.4K ﹤0.01% 2216
2025
Q1 		$626K Buy
77,843
+72,240
+1,289% +$585K ﹤0.01% 2219
2024
Q4 		$50.3K Sell
5,603
-62
-1% -$506 ﹤0.01% 2822
2024
Q3 		$41.5K Buy
5,665
+635
+13% +$3.94K ﹤0.01% 2819
2024
Q2 		$28.7K Buy
5,030
+4,678
+1,329% +$24.6K ﹤0.01% 2881
2024
Q1 		$1.76K Sell
352
-5
-1% -$34 ﹤0.01% 3084
2023
Q4 		$3.21K Buy
357
+133
+59% +$1.09K ﹤0.01% 2953
2023
Q3 		$1.74K Buy
+224
New +$2.19K ﹤0.01% 3282
2023
Q1 		– Sell
-22,215
Closed -$96K – 3294
2022
Q4 		$96K Buy
+22,215
New +$129K ﹤0.01% 2679
2020
Q2 		– Sell
-10,106
Closed -$145K – 3123
2020
Q1 		$145K Hold
10,106
– – ﹤0.01% 2634
2019
Q4 		$204K Buy
+10,106
New +$93.1K ﹤0.01% 2704

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Russell Investments Group's AUPH Position: Q2 2026 in Review

Russell Investments Group increased its Aurinia Pharmaceuticals (AUPH) stake by 8.7% in Q2 2026, buying an estimated $168K and bringing the position to 131,474 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

Russell Investments Group first reported a position in AUPH in Q4 2019 and has held it in 15 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Russell Investments Group held 131,474 shares of Aurinia Pharmaceuticals worth $2.23M as of Q2 2026.
  • Russell Investments Group bought 10,511 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $168K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2033 holding.
  • Russell Investments Group first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 15 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.